All In Biotech

Drug Trial Radar · NCT05500482

Vellore Typhoid Vaccine Impact Trial

Last checked: Nov 19, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 72,400 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

72,400

Actual

Start

May 1, 2023

Primary completion

Jan 31, 2026

Study completion Feb 28, 2026

Sponsor

Lead sponsor
Christian Medical College, Vellore, IndiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bill and Melinda Gates Foundation; University College, London; Imperial College London
First posted
Aug 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 1 year, up to 30 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This cluster randomised trial will examine the impact of introducing TyphiBEV, a typhoid conjugate vaccine licensed in India, on the incidence of typhoid fever in a high burden urban setting in South India.

Conditions

  • Typhoid Fever

Interventions

  • Typhoid conjugate VaccineBiological

    TyphiBEV is a clear colourless monovalent vaccine containing 25 µg of Typhoid Vi polysaccharide manufactured using the Citrobacter freundii sensu lato3056 (Vi) and is conjugated to CRM 197 as a carrier protein. Sodium chloride and Phosphate buffer are used as a buffering agent in the vaccine formulation with 2-Phenoxyethanol as a preservative.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total effectTime frame: at 24 months of follow up beginning 28 days after vaccine introduction in vaccine clusters.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Christian Medical College Vellore

    Vellore, Tamil Nadu, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.